内皮細胞由来弛緩因子 endothelium-derived relaxing factor
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/07/05 03:39:55」(JST)
[Wiki en表示]
Endothelium-derived relaxing factor (EDRF) is produced and released by the endothelium to promote smooth muscle relaxation. The best-characterized is nitric oxide (NO). Some sources equate EDRF and nitric oxide.[1]
It is released in response to a variety of chemical and physical stimuli. It causes the smooth muscle in the vessel wall to relax.
EDRF was discovered and characterized by Robert F. Furchgott, a winner of the Nobel Prize in Medicine in 1998 with his co-researchers Louis J. Ignarro and Ferid Murad.
Shortly after his death in May 2009, Furchgott's website at SUNY Downstate Medical Center continued to state that his group was "investigating whether the endothelium-derived relaxing factor (EDRF) is simply nitric oxide or a mixture of substances".[2]
Although there is strong evidence that nitric oxide elicits vasodilation, there is some evidence tying this effect to neuronal rather than endothelial reactions.[3]
References
- ^ "endothelial-derived relaxing factor" at Dorland's Medical Dictionary
- ^ "Robert Furchgott". Archived from the original on July 3, 2009. Retrieved 2015-03-16.
- ^ Chowdhary S, Townend JN (April 2001). "Nitric oxide and hypertension: not just an endothelium derived relaxing factor!". J Hum Hypertens. 15 (4): 219–27. PMID 11319669. doi:10.1038/sj.jhh.1001165.
|
Nitric oxide signaling modulators
|
| Forms |
- Nitroxyl anion (NO−; oxonitrate(1-), hyponitrite anion)
- Nitric oxide (NO⋅; nitrogen monoxide)
- Nitrosonium (NO+; nitrosyl cation)
|
| Targets |
| sGC |
- Activators: Cinaciguat (BAY 58-2667)
- Riociguat (BAY 63-2521)
|
|
NO donors
(prodrugs) |
- Nitrates: Diethylene glycol dinitrate (DEGDN)
- Erythritol tetranitrate (ETN)
- Ethylene glycol dinitrate (EGDN; nitroglycol)
- Isosorbide mononitrate (ISMN)
- Isosorbide dinitrate (ISDN)
- Itramin tosilate
- Mannitol hexanitrate
- Naproxcinod (nitronaproxen; AZD-3582, HCT-3012)
- NCX-466
- NCX-2216
- NCX-4016
- NCX 4040
- NCX-4215
- Nicorandil
- Nipradilol (K-351)
- Nitrate (NO−
3)
- Nitroatorvastatin (NCX-6560)
- Nitroflurbiprofen (HCT-1026)
- Nitrofluvastatin
- Nitroglycerin (glyceryl trinitrate (GTN))
- Nitropravastatin (NCX-6550)
- Pentaerithrityl tetranitrate (PETN)
- Propatylnitrate
- Propylene glycol dinitrate (PGDN)
- Sodium trioxodinitrate (Angeli's salt)
- Tenitramine
- Trolnitrate
- Nitroso compounds/nitrites: Nitrite (NO−
2); O-Nitroso compounds (alkyl nitrites): Amyl nitrite (isoamyl nitrite, isopentyl nitrite)
- Cyclohexyl nitrite
- Ethyl nitrite
- Hexyl nitrite
- Isobutyl nitrite (2-methylpropyl nitrite)
- Isopropyl nitrite
- Methyl nitrite
- n-Butyl nitrite
- Pentyl nitrite
- tert-Butyl nitrite; S-Nitroso compounds (thionitrites): LA810
- S-Nitrosoalbumin (SNALB)
- S-Nitrosated AR545C
- S-Nitroso-N-acetylcysteine (SNAC)
- S-Nitroso-N-acetylpenicillamine (SNAP)
- S-Nitroso-N-valerylpenicillamine (SNVP)
- S-Nitrosocaptopril (SNO-Cap)
- S-Nitrosocysteine (SNC, CysNO, SNO-Cys)
- S-Nitrosodiclofenac
- S-Nitrosoglutathione (GSNO, SNOG)
- SNO-t-PA
- SNO-vWF; N-Nitroso compounds (e.g., nitrosamines): SIN-1A
- Nitrosyl compounds: Metal nitrosyl complexes: Roussin's black salt
- Roussin's red salt
- Sodium nitroprusside (SNP)
- NONOates (diazeniumdiolates): Diethylamine/NO (DEA/NO)
- Diethylenetriamine/NO (DETA/NO)
- GLO/NO
- JS-K
- Methylamine hexamethylene methylamine/NO (MAHMA/NO)
- PROLI/NO
- Spermine/NO (SPER/NO)
- V-PYRRO/NO
- Heterocyclic compounds: Furoxans: Furoxan
- REC15/2739; Sydnonimines: Feprosidnine
- Linsidomine (SIN-1)
- Molsidomine (SIN-10)
- Sydnonimine
- Unsorted: CXL-1427
- FK-409
- FR144220
- FR146881
- N-Acetyl-N-acetoxy-4-chlorobenzenesulfonamide
|
Enzyme
(inhibitors) |
| NOS |
| nNOS |
- 3-Bromo-7-nitroindazole
- 3-Chloroindazole
- 3-Chloro-5-nitroindazole
- 5-Nitroindazole
- 6-Nitroindazole
- 7-Nitroindazole
- A-84643
- Aminoguanidine (pimagedine)
- ARL-17477
- Indazole
- N5-(1-Iminoethyl)-L-ornithine (L-NIO)
- Nω-Methyl-L-arginine (L-NMA)
- Nω-Propyl-L-arginine (L-NPA)
- Nitroarginine (NNA, NOARG)
- Pentamidine isethionate
- TRIM
|
| iNOS |
- 1-Amino-2-hydroxyguanidine
- 2-Ethylaminoguanidine
- 2-Iminopiperidine
- 1400W
- AEITU
- Aminoguanidine (pimagedine)
- AMT
- AR-C 102222
- BYK-191023
- Canavanine
- Cindunistat (SD-6010)
- EITU
- IPTU
- MITU
- N5-(1-Iminoethyl)-L-ornithine (L-NIO)
- N6-(1-Iminoethyl)-L-lysine (L-NIL)
- Nω-Methyl-L-arginine (L-NMA)
- Ronopterin (VAS-203)
- TRIM
|
| eNOS |
- Aminoguanidine (pimagedine)
- N5-(1-Iminoethyl)-L-ornithine (L-NIO)
- Nω-Methyl-L-arginine (L-NMA)
- Nitroarginine (NNA, NOARG)
|
| Unsorted |
- Asymmetric dimethylarginine (ADMA)
- CKD-712
- Guanidinoethyldisulfide (GED)
- GW-273629
- Indospicine
- KD-7040
- Nitroarginine methyl ester (NAME)
- NCX-456
- NXN-462
- ONO-1714
- VAS-2381
|
|
| Arginase |
- ABH
- Nω-Hydroxy-L-arginine (NOHA)
|
| CAMK |
|
|
| Others |
- Precursors: L-Arginine
- Nω-Hydroxy-L-arginine (NOHA)
- Cofactors: NADPH
- FAD
- FMN
- Heme
- BH4
- CaM
- O2
- Ca2+
- Indirect/downstream NO modulators: ACE inhibitors/AT-II receptor antagonists (e.g., captopril, losartan)
- ETB receptor antagonists (e.g., bosentan)
- L-Type calcium channel blockers (e.g., dihydropyridines: nifedipine)
- Nebivolol (beta blocker)
- PDE5 inhibitors (e.g., sildenafil)
- Statins (e.g., simvastatin)
|
|
See also: Receptor/signaling modulators
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- GRK2 as negative modulator of NO bioavailability: Implications for cardiovascular disease.
- Cannavo A1, Koch WJ2.
- Cellular signalling.Cell Signal.2017 Jan 7. pii: S0898-6568(17)30014-1. doi: 10.1016/j.cellsig.2017.01.014. [Epub ahead of print]
- PMID 28077324
- Endothelial dysfunction and vascular disease - a 30th anniversary update.
- Vanhoutte PM1, Shimokawa H2, Feletou M3, Tang EH1,4.
- Acta physiologica (Oxford, England).Acta Physiol (Oxf).2017 Jan;219(1):22-96. doi: 10.1111/apha.12646. Epub 2016 Jan 25.
- PMID 26706498
- Vascular Reactivity of Isolated Aorta to Study the Angiotensin-(1-7) Actions.
- Lautner RQ1,2, Fraga-Silva RA1,3, Ferreira AJ1,4, Santos RA5,6.
- Methods in molecular biology (Clifton, N.J.).Methods Mol Biol.2017;1527:369-379. doi: 10.1007/978-1-4939-6625-7_29.
- PMID 28116731
Japanese Journal
- 『虚血・代謝性冠微小血管拡張と過酸化水素』 冠微小循環と内皮由来過分極因子としての過酸化水素
- Linoleic Acid Attenuates Endothelium-Derived Relaxing Factor Production by Suppressing cAMP-Hydrolyzing Phosphodiesterase Activity
- Circulation journal : official journal of the Japanese Circulation Society 77(11), 2823-2830, 2013-10-25
- NAID 10031196837
- 臨床研究 ケルセチンの血管緊張に与える薬理作用について
Related Links
- 血管内皮細胞から産生されるNOには、血管拡張作用（降圧作用）があり、血管の内皮 由来弛緩因子（EDRF： endothelium -derived relaxing factor）と呼ばれていた。他に 血小板凝集抑制作用（抗動脈硬化作用）、血管平滑筋細胞の増殖を抑制する作用、 神経 ...
- Endothelium-derived relaxing factor (EDRF) is produced and released by the endothelium to promote smooth muscle relaxation. The best-characterized is nitric oxide (NO). Some sources equate EDRF and nitric oxide. It is released in ...
Related Pictures
★リンクテーブル★
[★]
- 英
- nitric-oxide synthase, nitric oxide synthase, NOS
- 同
- NOシンターゼ NO synthase
- 関
- 内皮細胞由来弛緩因子 EDRF
- L-アルギニンを基質として一酸化窒素を合成する酵素
- 一酸化窒素は生体膜を透過してシグナル伝達に関与する。
[★]
- 英
- endothelium-derived relaxing factor, EDRF
- 同
- 血管内皮細胞由来弛緩因子
- 関
- 内皮細胞
[★]
- 関
- also Nitric oxide
- 同
- EDRF
- 関
- Nitric oxide
- 関
- See also Nitric oxide
[★]
- 英
- [[]]
- 同
- EDRF
- 関
- [[]]
- 同
- EDRF
[★]